Amazon’s cloud computing division rolled out a new artificial intelligence platform on Tuesday that promises to revolutionize how pharmaceutical companies discover new medications.
The technology, called Amazon Bio Discovery, enables researchers to conduct sophisticated drug development processes without needing programming expertise, according to Amazon Web Services.
Pharmaceutical companies and tech firms have increasingly turned to artificial intelligence to streamline the traditionally lengthy drug development process.
Amazon Web Services explained in a company blog that their new platform provides scientists with access to specialized biological AI models capable of creating and analyzing potential medications, plus an AI assistant that guides users through model selection, parameter configuration, and result interpretation.
The system allows researchers to forward promising candidates to laboratory partners for creation and evaluation, with test outcomes feeding back into the platform to inform subsequent design cycles.
Rajiv Chopra, Amazon Web Services’ vice president of healthcare AI and life sciences, told Reuters that the technology dramatically cuts development time. “(It) would take, 18 months to come up with 300 potential drug candidates. Now, scientists can quickly create 300 candidates within a couple of weeks,” Chopra explained.
According to Chopra, the explosion of drug-discovery AI models has created a shortage of computational biologists capable of converting laboratory objectives into machine-learning systems.
Amazon Web Services reports that Bayer, the Broad Institute, and Voyager Therapeutics are testing the platform early, while 19 of the world’s 20 largest pharmaceutical companies currently utilize AWS cloud infrastructure.
In partnership with Memorial Sloan Kettering Cancer Center, the platform successfully created nearly 300,000 new antibody molecules and filtered them down to 100,000 testing candidates through partner Twist Bioscience, reducing months of traditional work to just weeks.
Chopra emphasized that the technology aims to support rather than eliminate scientists and contract research firms.
The company plans to provide a complimentary trial featuring five experimental units before rolling out paid subscription options.
Additionally, AWS, Boston Consulting Group, and Merck plan to introduce an AI system at AWS’s Life Science Symposium focused on enhancing clinical trial location selection, another frequent obstacle in pharmaceutical development.
